Trial Profile

A phase 1 clinical trial of ATL-201 for KCNT1-related epilepsy

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 10 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Apr 2025 According to Atalanta Therapeutics media release, the company plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for ATL-201 in 2025.
04 Feb 2025 New trial record
28 Jan 2025 According to an EQT Life Sciences media release, USD 75 million Series B financing will support Phase 1 clinical trials of the company's investigational RNAi therapies for KCNT1-related epilepsy and Huntington's disease.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com